IP and Patents

Stemedica International has an exclusive worldwide license for Stemedica Cell Technologies’ products for neurodegenerative diseases. As part of the license, Stemedica International also has full rights to any pre-clinical and clinical protocols and results of any pre-clinical and clinical trials associated with degenerative diseases.

Patents Issued

  • Culturing ectodermal cells under reduced oxygen tension in the presence of serum and a growth factor (U.S. Patent #8420394 B2)
  • Cellular Scaffold (U.S. Patent #8709081)
  • Cellular Scaffold – includes stem cell factors (U.S. Patent #8105380)
  • Compositions of Stem Cells and Stem Cell Factors and Methods for Their Use and Manufacture (U.S. Patent #8790638)

Patent Applications Filed With the United States Patent and Trademark Office

  • Mesenchymal Stem Cell Mediated Delivery of Therapeutic Agents
  • Angiogenically Induced Transplants and Methods for Their Use and Manufacture
  • Chimeric Transplant
  • Transgenic Therapeutic Stem Cells and Methods for their Use and Manufacture

Intellectual Property

Stemedica International’s other IP assets relate to the following processes:

  • Preserving Stem Cell Differentiation Potential During Scale-Up
  • Expansion/Scale-Up of Stem Cells
  • Treatment Protocols
  • Post-Treatment Patient Protocols
  • Cell Dosages and Number of Treatments Required for Therapeutic Effect